Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Dean G. Karalis"'
Publikováno v:
American Journal of Preventive Cardiology, Vol 14, Iss , Pp 100499- (2023)
Background: Effective control of risk factors in patients with ASCVD is important to reduce recurrent cardiovascular events. However, many ASCVD patients do not have their risk factors controlled, and this may have worsened during the COVID-19 pandem
Externí odkaz:
https://doaj.org/article/fe8f11d035524b678cc0fa377e5f3fb1
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 4, p 1382 (2023)
Hypertriglyceridemia (HTG) is a prevalent medical condition in patients with cardiometabolic risk factors and is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), if left undiagnosed and undertreated. Current guidel
Externí odkaz:
https://doaj.org/article/9d7f8b46338f43a0b79298c5464ece42
Publikováno v:
Journal of Clinical Medicine, Vol 10, Iss 17, p 3828 (2021)
Background: Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors reduce low-density lipoprotein (LDL) cholesterol and cardiovascular event rates, yet due to their high price remain underutilized and difficult to prescribe in clinical prac
Externí odkaz:
https://doaj.org/article/308d0ac716e84178b69da7dbdcb78090
Publikováno v:
Journal of Clinical Medicine, Vol 10, Iss 14, p 3090 (2021)
Heterozygous familial hypercholesterolemia (HeFH) creates elevated low-density lipoprotein cholesterol (LDL-C), causing premature atherosclerotic cardiovascular disease (ASCVD). Guidelines recommend cascade screening relatives and starting statin the
Externí odkaz:
https://doaj.org/article/e1a595d47f6c45e6b3e89a2f6918ad99
Publikováno v:
Clinical cardiologyREFERENCES.
Despite the availability of effective therapies that lower low-density lipoprotein cholesterol (LDL-C) levels in patients with atherosclerotic cardiovascular disease, many eligible patients are inadequately treated and their LDL-C levels remain subop
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 3828, p 3828 (2021)
Volume 10
Issue 17
Journal of Clinical Medicine, Vol 10, Iss 3828, p 3828 (2021)
Volume 10
Issue 17
Background: Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors reduce low-density lipoprotein (LDL) cholesterol and cardiovascular event rates, yet due to their high price remain underutilized and difficult to prescribe in clinical prac
Publikováno v:
Journal of clinical medicine, vol 10, iss 14
Journal of Clinical Medicine
Volume 10
Issue 14
Journal of Clinical Medicine, Vol 10, Iss 3090, p 3090 (2021)
Journal of Clinical Medicine
Volume 10
Issue 14
Journal of Clinical Medicine, Vol 10, Iss 3090, p 3090 (2021)
Heterozygous familial hypercholesterolemia (HeFH) creates elevated low-density lipoprotein cholesterol (LDL-C), causing premature atherosclerotic cardiovascular disease (ASCVD). Guidelines recommend cascade screening relatives and starting statin the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb3c5e1d143203fb925130a863819e53
https://escholarship.org/uc/item/10m9971s
https://escholarship.org/uc/item/10m9971s
Publikováno v:
The American Journal of Cardiology.
Heterozygous familial hypercholesterolemia (HeFH) results in significant elevations in LDL-C and premature atherosclerotic cardiovascular disease (ASCVD). Current guidelines recommend add-on proprotein subtilisin/kexin type 9 inhibitor (PCSK9i) thera
Publikováno v:
Journal of Clinical Lipidology. 16:e4-e5
Publikováno v:
Journal of clinical lipidology. 15(5)
HeFH is a common inherited disorder that leads to markedly elevated LDL-cholesterol from birth and premature cardiovascular disease. HeFH is frequently underdiagnosed and undertreated.To compare how well primary care physicians and cardiologists reco